[anakinra (new indication), bamlanivimab, baricitinib (new indication), BBIBP-CorV, belimumab (new indication), calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate (new formulation), casirivimab/imdevimab, ensartinib hydrochloride, favipiravir (new indication), Gam-COVID-Vac, inactivated SARS-CoV-2 vaccine, loteprednol etabonate (new indication), lumasiran (first-in-class), mRNA-1273, rilonacept (new indication), tozinameran].
© 2001-2025 Fundación Dialnet · Todos los derechos reservados